Abstract

Protein phosphatase 2A (PP2A) is a highly conserved and ubiquitous serine/threonine phosphatase. We have shown previously that PP2A expression is increased in T cells of systemic lupus erythematosus patients and that this increased expression and activity of PP2A plays a central role in the molecular pathogenesis of systemic lupus erythematosus. Although the control of PP2A expression has been the focus of many studies, many aspects of its regulation still remain poorly understood. In this study, we describe a novel mechanism of PP2A regulation. We propose that the transcription factor Ikaros binds to a variant site in the first intron of PP2A and modulates its expression. Exogenous expression of Ikaros leads to reduced levels of PP2Ac message as well as protein. Conversely, siRNA-enabled silencing of Ikaros enhances the expression of PP2A, suggesting that Ikaros acts as a suppressor of PP2A expression. A ChIP analysis further proved that Ikaros is recruited to this site in T cells. We also attempted to delineate the mechanism of Ikaros-mediated PP2Ac gene suppression. We show that Ikaros-mediated suppression of PP2A expression is at least partially dependent on the recruitment of the histone deacetylase HDAC1 to this intronic site. We conclude that the transcription factor Ikaros can regulate the expression of PP2A by binding to a site in the first intron and modulating chromatin modifications at this site via recruitment of HDAC1.

Highlights

  • phosphatase 2A (PP2A) is a serine/threonine phosphatase playing a central role in the pathology of the autoimmune disease Systemic lupus erythematosus (SLE)

  • We have shown previously that PP2A expression is increased in T cells of systemic lupus erythematosus patients and that this increased expression and activity of PP2A plays a central role in the molecular pathogenesis of systemic lupus erythematosus

  • In this study we propose a novel mechanism for regulating the expression of PP2A, a serine/threonine phosphatase that is central to the molecular defects seen in the pathogenesis of SLE

Read more

Summary

Background

PP2A is a serine/threonine phosphatase playing a central role in the pathology of the autoimmune disease SLE. We conclude that the transcription factor Ikaros can regulate the expression of PP2A by binding to a site in the first intron and modulating chromatin modifications at this site via recruitment of HDAC1. We have shown previously that PP2A protein and mRNA levels as well as the enzymatic activity of the catalytic subunit are increased in T cells from SLE patients compared with healthy individuals (9) This enhanced expression of PP2A is one of the factors contributing to the molecular defects seen in SLE (10). We demonstrate, for the first time, that Ikaros acts as a repressor for the serine/threonine phosphatase PP2A and, identify a novel means of control of PP2A, a critical molecule involved in lupus pathogenesis

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call